Development
Dyne Therapeutics, Inc.
DYN
$10.47
$0.222.15%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 31.40M | 29.51M | 30.10M | 28.58M | 28.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 242.16M | 214.62M | 194.62M | 180.64M | 170.96M |
| Operating Income | -242.16M | -214.62M | -194.62M | -180.64M | -170.96M |
| Income Before Tax | -235.94M | -208.13M | -189.30M | -176.70M | -168.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -235.94 | -208.13 | -189.30 | -176.70 | -168.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -235.94M | -208.13M | -189.30M | -176.70M | -168.10M |
| EBIT | -242.16M | -214.62M | -194.62M | -180.64M | -170.96M |
| EBITDA | -240.49M | -212.94M | -192.98M | -178.97M | -169.28M |
| EPS Basic | -3.94 | -3.59 | -3.40 | -3.33 | -3.24 |
| Normalized Basic EPS | -2.46 | -2.24 | -2.13 | -2.08 | -2.02 |
| EPS Diluted | -3.94 | -3.59 | -3.40 | -3.33 | -3.24 |
| Normalized Diluted EPS | -2.46 | -2.24 | -2.13 | -2.08 | -2.02 |
| Average Basic Shares Outstanding | 238.66M | 230.09M | 220.77M | 212.62M | 207.89M |
| Average Diluted Shares Outstanding | 238.66M | 230.09M | 220.77M | 212.62M | 207.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |